Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 11/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995169 | 0.91 | CETP (0.40) | CETPHCRTR1HCRTR2HTR2CSLC6A4 | |
| SCHEMBL994666 | 0.90 | CETP (0.36) | CETPHCRTR1HCRTR2HRH4HTR2C | |
| SCHEMBL993525 | 0.88 | IDH1 (0.35) | CETPHCRTR1HCRTR2HRH4IDH1 | |
| SCHEMBL992310 | 0.87 | CETP (0.43) | CETP | |
| SCHEMBL993681 | 0.85 | CETP (0.36) | CETPHCRTR1HCRTR2HRH4ADRB1 | |
| SCHEMBL1244525 | 0.83 | CETP (0.35) | CETPHCRTR1HCRTR2HRH4IDH1 | |
| SCHEMBL994074 | 0.80 | CETP (0.43) | CETPHTR2CSLC6A4HTR2B | |
| SCHEMBL5670975 | 0.69 | IDH2 (0.33) | ADRB1IDH1 | |
| SCHEMBL1901254 | 0.69 | SLC6A2 (0.47) | SLC6A4 | |
| SCHEMBL993969 | 0.69 | SLC6A2 (0.51) | CETPSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468604-B2 | Pharmaceutical compositions of dispersions of drug and neutral polymers | BEND RESEARCH, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8703196-B2 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703199-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8389006-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389011-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000226-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000294-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000238-A1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUG | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CETP 1/4885HCRTR1 4590/4885HCRTR2 4539/4885 |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CETP 1/4885HCRTR1 4590/4885HCRTR2 4539/4885 |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CETP 1/4885HCRTR1 2553/4885HCRTR2 2609/4885 |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | CETP 1/4885HCRTR1 3009/4885HCRTR2 3537/4885 |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CETP 227/4885HCRTR1 4809/4885HCRTR2 4780/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CETP 1/4885HCRTR1 2669/4885HCRTR2 2046/4885 |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CETP 227/4885HCRTR1 4809/4885HCRTR2 4780/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CETP 1/4885HCRTR1 2553/4885HCRTR2 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.